Dr Ashish Misra awarded Perpetual IMPACT grant
Dr Ashish Misra, leader of the Atherosclerosis and Vascular Remodelling Unit at HRI, has been awarded the Perpetual IMPACT grant.
Unprecedented drug design minimising side effects
HRI has developed an unprecedented drug design strategy that tailors drugs with fatty acids to minimise side effects.
Global media interest in HRI’s breakthrough anti-clotting drug for COVID-19
The revolutionary new anti-clotting medicine developed by HRI has attracted global media interest due to its far-reaching impact.
HRI researchers on cusp of worldwide breakthrough in COVID-19 treatment
Researchers at HRI believe they may hold the key to controlling the deadly blood clots caused by COVID-19.
HRI announces novel anti-clotting drug to help critically ill COVID-19 patients
HRI is on the precipice of a significant research breakthrough for the treatment of one of the major life-threatening complications of the novel coronavirus (COVID-19), microscopic blood clots.
Cardiovascular Medical Devices Group reviews next-generation surfaces
HRI's Cardiovascular Medical Devices Group reviews next-generation liquid-infused surfaces that could be used to improve medical devices like heart bypass machines.
HRI undertakes critical research into COVID-19-related heart disease
The Heart Research Institute, in partnership with major NSW hospitals, universities, and other research institutions, is striving to unravel the deadly link between the coronavirus (COVID-19) and cardiovascular disease.
Revealed: The molecule messing with your gym workout
Research by HRI explains why some people fail to shed pounds and lower cholesterol even when eating well and exercising hard.
A landslide win for HRI researchers
Seven of HRI's scientists have been recognised as world leaders in their research fields with the award of prestigious NSW Cardiovascular Research Capacity Building Grants for their work.